Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evotec AG (EVO)
NASDAQ:EVO
Holding EVO?
Track your performance easily
EVO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.85 - $12.00
Previous Close$4.47
Volume1.73M
Average Volume (3M)234.16K
Market Cap
$1.54B
Enterprise Value$907.61M
Total Cash (Recent Filing)€604.11M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Mar 27, 2025EPS Estimate
-$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding354,371,472
10 Day Avg. Volume454,705
30 Day Avg. Volume234,157
Standard Deviation0.14
R-Squared0.26
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.42
Price to Sales (P/S)6.95
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.27Price Target Upside62.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Evotec AG News
Bulls Say, Bears Say
Bulls Say
Cost EfficiencyThe strategy should improve the company's cost efficiency.
Financial PerformanceManagement is confident in the Q4 performance based on their current order book outlook and their fixed cost increase in revenue, which is expected to lead to a profit uplift.
Strategic PartnershipsEvotec recently expanded its BMY molecular glue collab and initiated a cell therapy collab with Novo Nordisk.
Bears Say
Expense StructureManagement explained that the reduction of revenue and adjusted EBITDA expectations were due to the challenging environment and the high fixed cost base.
Financial PerformanceEVO’s current forward visibility is severely limited, with potential for further cuts to FY25 estimates in coming quarters.
RevenueRepeated significant guide cuts indicate that EVO continues to face both idiosyncratic and industry-wide challenges.
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.40% Other Institutional Investors
98.59% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
EVO FAQ
What was Evotec AG’s price range in the past 12 months?
Evotec AG lowest stock price was $2.85 and its highest was $12.00 in the past 12 months.
What is Evotec AG’s market cap?
Currently, no data Available
When is Evotec AG’s upcoming earnings report date?
Evotec AG’s upcoming earnings report date is Mar 27, 2025 which is in 95 days.
How were Evotec AG’s earnings last quarter?
Evotec AG released its earnings results on Nov 06, 2024. The company reported -$0.118 earnings per share for the quarter, missing the consensus estimate of -$0.06 by -$0.058.
Is Evotec AG overvalued?
According to Wall Street analysts Evotec AG’s price is currently Undervalued.
Does Evotec AG pay dividends?
Evotec AG does not currently pay dividends.
What is Evotec AG’s EPS estimate?
Evotec AG’s EPS estimate is -$0.04.
How many shares outstanding does Evotec AG have?
Evotec AG has 355,106,900 shares outstanding.
What happened to Evotec AG’s price movement after its last earnings report?
Evotec AG reported an EPS of -$0.118 in its last earnings report, missing expectations of -$0.06. Following the earnings report the stock price went down -15.721%.
Which hedge fund is a major shareholder of Evotec AG?
Currently, no hedge funds are holding shares in EVO
---
Evotec AG Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.27 (62.64% Upside)
$7.27 (62.64% Upside)
Blogger Sentiment
Bullish
EVO Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.47%
12-Months-Change
Fundamentals
Return on Equity
-16.21%
Trailing 12-Months
Asset Growth
-6.92%
Trailing 12-Months
Company Description
Evotec AG
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
---
EVO Company Deck
---
EVO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook for Evotec SE. While there were significant achievements in the Just - Evotec Biologics segment with substantial revenue growth and strong liquidity, challenges persist in the Shared R&D segment with revenue declines and reduced margins. The company is focusing on cost optimization and has promising partnerships, but profitability remains under pressure.Read More>---
EVO Stock 12 Month Forecast
Average Price Target
$7.27
▲(62.64% Upside)
Technical Analysis
Best Analysts Covering EVO
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-15.61%
reiterated a buy rating 2 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -15.61% per trade.
---